Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 8/20 | 0.39 |
| ▸ | EGFR | P00533 | 6/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706766 | 0.92 | EGFR (0.38) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL4689937 | 0.92 | FGFR4 (0.40) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| Acetic Acid SCHEMBL4686845 | 0.91 | FGFR4 (0.38) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL4690757 | 0.91 | FGFR4 (0.39) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| Acetic Acid SCHEMBL4687570 | 0.90 | EGFR (0.37) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL4686754 | 0.89 | EGFR (0.38) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL14290437 | 0.89 | EGFR (0.38) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL6212461 | 0.89 | EGFR (0.38) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL4686694 | 0.88 | FGFR4 (0.39) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL4686091 | 0.87 | MMP2 (0.40) | MAPK1ALDH1A1MAPTSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556384-B1 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | claimed |
| US-7084270-B2 | Pyrimido compounds having antiproliferative activity | HOFFMAN-LA ROCHE INC. (US) | 2006-08-01 | — | — | US | claimed |
| EP-1556384-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-27 | — | — | EP | claimed |
| WO-2004018472-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-04 | — | — | WO | claimed |
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-02-26 | — | — | US | claimed |
| EP-1556384-B1 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-7084270-B2 | Pyrimido compounds having antiproliferative activity | HOFFMAN-LA ROCHE INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1556384-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004018472-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-04 | — | — | WO | disclosed |
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | LCK, FGFR1, FGFR3 | FGFR4 5/4885EGFR 45/4885PDGFRB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.